Your browser doesn't support javascript.
loading
Structures, functions and adaptations of the human LINE-1 ORF2 protein.
Baldwin, Eric T; van Eeuwen, Trevor; Hoyos, David; Zalevsky, Arthur; Tchesnokov, Egor P; Sánchez, Roberto; Miller, Bryant D; Di Stefano, Luciano H; Ruiz, Francesc Xavier; Hancock, Matthew; Isik, Esin; Mendez-Dorantes, Carlos; Walpole, Thomas; Nichols, Charles; Wan, Paul; Riento, Kirsi; Halls-Kass, Rowan; Augustin, Martin; Lammens, Alfred; Jestel, Anja; Upla, Paula; Xibinaku, Kera; Congreve, Samantha; Hennink, Maximiliaan; Rogala, Kacper B; Schneider, Anna M; Fairman, Jennifer E; Christensen, Shawn M; Desrosiers, Brian; Bisacchi, Gregory S; Saunders, Oliver L; Hafeez, Nafeeza; Miao, Wenyan; Kapeller, Rosana; Zaller, Dennis M; Sali, Andrej; Weichenrieder, Oliver; Burns, Kathleen H; Götte, Matthias; Rout, Michael P; Arnold, Eddy; Greenbaum, Benjamin D; Romero, Donna L; LaCava, John; Taylor, Martin S.
Afiliação
  • Baldwin ET; ROME Therapeutics, Boston, MA, USA.
  • van Eeuwen T; Laboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY, USA.
  • Hoyos D; Computational Oncology, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Zalevsky A; Department of Bioengineering and Therapeutic Sciences University of California, San Francisco, San Francisco, CA, USA.
  • Tchesnokov EP; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
  • Sánchez R; Quantitative Biology Institute, University of California, San Francisco, San Francisco, CA, USA.
  • Miller BD; Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada.
  • Di Stefano LH; ROME Therapeutics, Boston, MA, USA.
  • Ruiz FX; Department of Pathology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Hancock M; European Research Institute for the Biology of Ageing, University Medical Center Groningen, Groningen, The Netherlands.
  • Isik E; Center for Advanced Biotechnology and Medicine and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway, NJ, USA.
  • Mendez-Dorantes C; Department of Bioengineering and Therapeutic Sciences University of California, San Francisco, San Francisco, CA, USA.
  • Walpole T; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
  • Nichols C; Quantitative Biology Institute, University of California, San Francisco, San Francisco, CA, USA.
  • Wan P; Department of Pathology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Riento K; Department of Pathology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Halls-Kass R; Charles River Laboratories, Chesterford Research Park, Saffron Walden, UK.
  • Augustin M; Charles River Laboratories, Chesterford Research Park, Saffron Walden, UK.
  • Lammens A; Charles River Laboratories, Chesterford Research Park, Saffron Walden, UK.
  • Jestel A; Charles River Laboratories, Chesterford Research Park, Saffron Walden, UK.
  • Upla P; Charles River Laboratories, Chesterford Research Park, Saffron Walden, UK.
  • Xibinaku K; Proteros Biostructures GmbH, Martinsried, Planegg, Germany.
  • Congreve S; Proteros Biostructures GmbH, Martinsried, Planegg, Germany.
  • Hennink M; Proteros Biostructures GmbH, Martinsried, Planegg, Germany.
  • Rogala KB; Laboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY, USA.
  • Schneider AM; Whitehead Institute for Biomedical Research, Cambridge, MA, USA.
  • Fairman JE; Whitehead Institute for Biomedical Research, Cambridge, MA, USA.
  • Christensen SM; Whitehead Institute for Biomedical Research, Cambridge, MA, USA.
  • Desrosiers B; Department of Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.
  • Bisacchi GS; Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA.
  • Saunders OL; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
  • Hafeez N; Structural Biology of Selfish RNA, Department of Protein Evolution, Max Planck Institute for Biology, Tübingen, Germany.
  • Miao W; Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Kapeller R; Department of Biology, University of Texas at Arlington, Arlington, TX, USA.
  • Zaller DM; ROME Therapeutics, Boston, MA, USA.
  • Sali A; ROME Therapeutics, Boston, MA, USA.
  • Weichenrieder O; ROME Therapeutics, Boston, MA, USA.
  • Burns KH; ROME Therapeutics, Boston, MA, USA.
  • Götte M; ROME Therapeutics, Boston, MA, USA.
  • Rout MP; ROME Therapeutics, Boston, MA, USA.
  • Arnold E; ROME Therapeutics, Boston, MA, USA.
  • Greenbaum BD; Department of Bioengineering and Therapeutic Sciences University of California, San Francisco, San Francisco, CA, USA.
  • Romero DL; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
  • LaCava J; Quantitative Biology Institute, University of California, San Francisco, San Francisco, CA, USA.
  • Taylor MS; Structural Biology of Selfish RNA, Department of Protein Evolution, Max Planck Institute for Biology, Tübingen, Germany.
Nature ; 626(7997): 194-206, 2024 Feb.
Article em En | MEDLINE | ID: mdl-38096902
ABSTRACT
The LINE-1 (L1) retrotransposon is an ancient genetic parasite that has written around one-third of the human genome through a 'copy and paste' mechanism catalysed by its multifunctional enzyme, open reading frame 2 protein (ORF2p)1. ORF2p reverse transcriptase (RT) and endonuclease activities have been implicated in the pathophysiology of cancer2,3, autoimmunity4,5 and ageing6,7, making ORF2p a potential therapeutic target. However, a lack of structural and mechanistic knowledge has hampered efforts to rationally exploit it. We report structures of the human ORF2p 'core' (residues 238-1061, including the RT domain) by X-ray crystallography and cryo-electron microscopy in several conformational states. Our analyses identified two previously undescribed folded domains, extensive contacts to RNA templates and associated adaptations that contribute to unique aspects of the L1 replication cycle. Computed integrative structural models of full-length ORF2p show a dynamic closed-ring conformation that appears to open during retrotransposition. We characterize ORF2p RT inhibition and reveal its underlying structural basis. Imaging and biochemistry show that non-canonical cytosolic ORF2p RT activity can produce RNADNA hybrids, activating innate immune signalling through cGAS/STING and resulting in interferon production6-8. In contrast to retroviral RTs, L1 RT is efficiently primed by short RNAs and hairpins, which probably explains cytosolic priming. Other biochemical activities including processivity, DNA-directed polymerization, non-templated base addition and template switching together allow us to propose a revised L1 insertion model. Finally, our evolutionary analysis demonstrates structural conservation between ORF2p and other RNA- and DNA-dependent polymerases. We therefore provide key mechanistic insights into L1 polymerization and insertion, shed light on the evolutionary history of L1 and enable rational drug development targeting L1.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: DNA Polimerase Dirigida por RNA / Elementos Nucleotídeos Longos e Dispersos / Transcrição Reversa / Endonucleases Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: DNA Polimerase Dirigida por RNA / Elementos Nucleotídeos Longos e Dispersos / Transcrição Reversa / Endonucleases Idioma: En Ano de publicação: 2024 Tipo de documento: Article